Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The long term survival of a 78 year old female diagnosed with Malignant Epithelial Mesothelioma with peritoneal disease on Pembrolizumab plus Pemetrexed and Carboplatin: a case report

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Katherine Ruth Oracion

Authors

K.R.S. Oracion1, G.D.H. Cornelio2

Author affiliations

  • 1 Internal Medicine, St Lukes Medical Center Global City, 1634 - Taguig City/PH
  • 2 Cancer Institute, St Lukes Medical Center Global City, 1634 - Taguig City/PH
More

Resources

Case Summary

Mesothelioma is a rare disease with an overall survival rate of 1 year and a 5 year survival rate of about 10%. Recently, pembrolizumab in combination with pemetrexed and carboplatin was approved by FDA as the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. This is a case of a 78 year old female diagnosed for 6 years with Malignant pleural epithelial mesothelioma extending to the peritoneum. This initially manifested as back pain with an ECOG performance status of 0. 2 months after diagnosis, patient was managed with Intensity-modulated radiation therapy(IMRT) for 1 month with no response. Patient then underwent pressurized intraperitoneal/intrathoracal aerosol chemotherapy (PIPAC/PITAC) with cisplatin and doxorubicin for 3 doses still with no response. She then enrolled on a clinical trial of LY3023414 at Memorial Sloan Kettering Cancer Center for 1 month. However, she withdrew from the trial and went back to the Philippines to try immunotherapy with pembrolizumab every 3 weeks. With disease progression after 1 year, patient was then given pemetrexed and carboplatin (pem/carbo) plus pembrolizumab every 21 days for 1 year until present. This is a rare case of a long tern survival of malignant mesothelioma for 6 years.

Editorial acknowledgement

Clinical trial identification

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings